Synergistische Effekte von Celecoxib und Flavopiridol beim humanen Ovarialkarzinom in vitro

Grundlage dieser Dissertation ist die medikamentöse Behandlung von zwei epithelialen humanen Ovarialkarzinomzelllinien (SKOV-3- und BG-1-Zellen) in vitro. Bei den Medikamenten handelt es sich um Celecoxib, einen Hemmer der COX-2, ursprünglich entwickelt für die analgetische Therapie, z.B. bei Rheu...

Full description

Saved in:
Bibliographic Details
Main Author: Klingebiel, Stefanie
Contributors: Wagner, Uwe (Prof.) (Thesis advisor)
Format: Dissertation
Published: Philipps-Universität Marburg 2011
Frauenheilkunde und Geburtshilfe
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

1. (105) Narayanan, B.A., Condon, M.S., Bosland, M.C., Narayanan, N.K., Reddy, B.S.: Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanisms. Clin Cancer Res 15; 9(9): S. 3503 – 13 (2003).

2. Shapiro, G.I., Supko, J.G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P.F., Muzikansky, A., Wright, J.J., Lynch, T.J. Jr, Rollins, B.J.: A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7(6). S. 1590-9 (2001).

3. Mayer, F., Mueller, S., Malenke, E., Kuczyk, M., Hartmann, J.T. and Bokemeyer, C.: Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Investigational New Drugs 23 (3): S. 205–211 (2005).

4. Trimbos, J.B., Vergote, I., Bolis, G. , Vermorken, J.B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., Giurgea, L., Timmers, P., Coens, C., Pecorelli, S.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in ovarian Neoplasm trial. Bde. J Natl Cancer Inst 95:113-25 (2003).

5. Wennerberg, K., Rossman, K.L., and Channing, J. Der.: The Ras superfamily at a glance. Journal of Cell Science 118, S. 843-846 (2005).

6. (173) Wall, N.R., O'Connor, D.S., Plescia, J., Pommier, Y., Altieri, D.C.: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Research 1;63(1): S. 230-5 (2003).

7. (179) West, K.A., Castillo, S.S., Dennis, P.A.: Activation of the PI3K/AKT pathway and chemotherapeutic resistance. Drug Resist. Updat. 5(6): S. 234-48 (2002).

8. (98) Meyerson, M., Enders, G.H., Wu, C.L. et al.: A family of human cdc2-related protein kinases. EMBO J 11: S. 2909-17 (1992)

9. (158) Sun, M., Wang, G., Paciga, J.E., Feldman, R.I., Yuan, Z.Q., Ma, X.L., Shelley, S.A., Jove, R., Tsichlis, P.N., Nicosia, S.V., Cheng, J.Q.: AKT1/PKB-alpha-kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159(2): S. 431-7 (2001).

10. (180) Worland, P., Kaur, G., Stetler-Stevenson, M., et al.: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol 46: S. 1831–40 (1993).

11. (142) Shah, M.A., Kortmansky, J., Motwani, M., Drobnjak, M., Gonen, M., Yi, S., Weyerbacher, A., Cordon-Cardo, C., Lefkowitz, R., Brenner, B., O'Reilly, E., Saltz, L., Tong, W., Kelsen, D.P., Schwartz, G.K.: A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res. 15;11(10): S. 3836-45 (2005).

12. Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., Villalba, L., Hill, K., Steinberg, S.M., Figg, W.D., Tompkins, A., Arbuck, S.G., Sausville, E.A.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16(9). S. 2986-99 (1998).

13. Motwani, M., Jung, C., Sirotnak, F.M., She, Y., Shah, M.A., Gonen, M., Schwartz G.K.: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res.7(12): S. 4209-19 (2007).

14. Sherr, C.J.: Cancer cell cycles. Science 274: S. 1672 (1996).

15. (109) Pastorekova, S., Kopacek, J., Pastorek, J.: Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 7(9): 865–878 (2007).

16. Malumbres, M., Pevarello, P., Barbacid, M. and Bischoff, J.R.: CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci. 29(1):16-21 (2008).

17. Sherr, C.J., Roberts, J.M.: CDK inhibitors: positive and negative regulators of G1- phase progression. Genes Dev 13: S. 1501–12 (1999).

18. (190) Zhang, Z., Lai, G.H., Sirica, A.E.: Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39 : S. 1028 – 37 (2004).

19. (172) Vital-Reyes, V., Rodríguez-Burford, C., Chhieng, D.C., Oelschlager, D.K., Reyes- Fuentes, A., Barnes, M., Grizzle, W.E.: Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med Res 37(6): S. 689-95 (2006).

20. Wu, G., Yi, J., Di, F., Zou, S., Li, X.: Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 25(1): S. 42-4 (2005).

21. Patel, M.I., Subbaramaiah, K., Du, B., Chang, M., Yang, P., Newman, R.A., et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 1;11(5):1999 – 2007 (2005).

22. (107) Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C. et al.: Celecoxib loses its anti-infl ammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15 : S. 1622 – 4 (2001).

23. Martin, K.A., Blenis, J.: Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res. 86: S. 1-39 (2002).

24. Muise-Helmericks, R.C., Grimes, H.L., Bellacosa, A., Malstrom, S.E., Tsichlis, P.N., Rosen, N.: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 6;273(45): S. 29864-72 (1998).

25. (155) Soumaoro, L.T., Uetake, H., Higuchi T., Takagi Y., Enomoto M. and Sugihara K.: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10, S. 8465–8471 (2004).

26. Wulfing, C., Eltze, E., von Struensee, D., Wulfing, P., Hertle, L. and Piechota H.: Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 45, S. 46-52 (2004).

27. (159) Symowicz, J., Adley, B.P., Woo, M.M.M., Auersperg, N., Hudson, L.G. and Stack, M,S.: Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells. Cancer Research 65, S. 2234-2242 (2005).

28. (90) Makhija, S., Husain, A., Schwartz, G.K., Spriggs, D.R.: Cytotoxicity of Flavopiridol in ovarian cancer cells, alone and in combination with CDDP. Proc Am Assoc Cancer Res 38:320 (1997).

29. (103) Munkarah, A.R., Morris. R., Baumannk, P,. Deppe, G., Malone, J., Diamond, M.P., Saed, G.M.: Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig 9(3): S. 168-73 (2002).

30. Stadler, W.M., Vogelzang, N.J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., Vokes, E.E.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 18(2): S. 371-5 (2000).

31. (97) Melillo, G., Sausville, E.A., Cloud, K. et al: Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 59: S. 5433-5437 (1999).

32. (94) Mason, K.A. M.S., Hunter N.R., M.S., Raju U., Ph.D., Ariga H., M.D., Ph.D., Husain A., M.D., Valdecanas D., B.S. et al.: Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int. J. Radiation Oncology Biol. Phys., Vol. 59, No. 4, S. 1181-1189 (2004).

33. (145) Shapiro, G.I., Koestner, D.A., Matranga, C.B. and Rollins, B.J.: Flavopiridol Induces Cell Cycle Arrest and p53-independent Apoptosis in Non-Small Cell Lung Cancer Cell Lines. Clinical Cancer Research Vol. 5, S. 2925–2938 (1999).

34. Takada, Y., Aggarwal. B.B.: Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 6;279(6). S. 4750-9 (2004).

35. Newcomb, E.W.: Flavopiridol : pleiotropic biological effects enhance its anti-cancer activity. Review. Anticancer Drugs, 15(5): S. 411-9 (2004).

36. Shinn, C., Larsen, D., Suarez, J.R.: Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding. Blood 96:294b (2000).

37. (188) Yuan, Z.Q., Sun. M., Feldman, R.I., Wang, G., Ma, X., Jiang, C., Coppola, D., Nicosia, S.V., Cheng, J.Q.: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 4;19(19): S. 2324-30 (2000).

38. Sherr, C.J.: G1 phase progression: Cycling on cue. Cell 79, S. 551-555 (1994).

39. (191) Zhu, G., Saed, G.M., Deppe, G., Diamond, M.P., Munkarah, A.R.: Hypoxia up- regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. Gynecol Oncol 94(2): S. 422-6 (2004).

40. (184) Wun, T., McKnight, H., Tuscano, J.M.: Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 28 : S. 179 – 90 (2004).

41. Sherr, C.J., Roberts, J.M..: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: S. 1149–63 (1995).

42. (104) Nam, D.H., Park, K., Park, C., Im, Y.H., Kim, M.H., Lee, S., et al.: Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 11 : S. 263 – 8 (2004).

43. (164) Tanaka, K., Tomisato, W., Hoshino, T., Ishihara, T., Namba, T., Aburaya, M., Katsu, T., Suzuki, K., Tsutsumi, S., Mizushima, T.: Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem. 280(35):31059-67 (2005).

44. Luo Cheng, He Ming-liang and Bohlin, Lars: Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial. Review. Acta Pharmacologica Sinica 26 (8): 926–933 (2005).

45. Morice, P., Joulie, F., Cammate, S., Atallah, D., Rouzier, R., Pautier, P., Pomel, C., Duvillard, P., Castaigne, D.: Lymph Node involvementin epithelial ovarian cancer: analysis of 276 pelvic and paaaortic lymphadenectomies and surgical implications. J Am Coll Surg, Bde. 197:198-205 (2003).

46. Malumbres, M., Sotillo, R., Santamaria, D. et al: Mammalian cells cycle without the D-type cyclindependent kinases Cdk4 and Cdk6. Cell 118: S. 493-504 (2004).

47. Steinbild, S., Arends, J., Medinger, M., Häring, B., Frost, A., Drevs, J., Unger, C., Strecker, R., Hennig, J., Mross, K.: Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase II study. Onkologie 30(12): S. 629-35 (2007).

48. Senderowics, A.M.: Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharamcol 52 (Suppl 1): S. 61-73 (2003).

49. (138) Senderowicz, A.M.: Novel small-molecule cyclin-dependent kinase modulators in human clinical trials. Cancer Biology & Therapy, 2(4:Suppl): S. 84-95 (2003).

50. (162) Tan, A.R., Headlee, D., Messmann, R., Sausville, E.A., Arbuck, S.G., Murgo, A.J., Melillo, G., Zha, S., Figg, W.D., Swain, S.M., Senderowicz, A.M.: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 1;20(19). S. 4074-82 (2002).

51. (163) Tan, A.R., Yang, X., Berman, A., Zhai, S., Sparreboom, A., Parr, A.L., Chow, C., Brahim, J.S., Steinberg, S.M., Figg, W.D., Swain, S.M.: Phase I trial of the cyclin- dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 1;10(15). -2004. -S. 5038-47 (2004).

52. (147) Shayesteh, L., Lu, Y., Kuo, W.L., Baldocci, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G.B., Gray, J.W.: PIK3Ca is implicated as an oncogene in ovarian cancer. Nat Genet 21(1): S. 99-102 (1999).

53. Shapiro, G. I.: Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol. Clinical Cancer Research 15;10(12Pt 2): S. 4270–4275 (2004).

54. Tetsu, O., McCormick, F.: Proliferation of cancer cells despite cdk2 inhibition. Cancer Cell 3: S. 233-245 (2003).

55. (174) Wang, D., Buchanan, F.G., Wang, H., Dey, S.K., DuBois, R.N.: Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65:1822–9 (2005).

56. (175) Wang, D., Dubois, R.N.: Prostaglandins and cancer. Gut 55:115–22 (2006).

57. (111) Peluffo, G.D., Stillitani, I., Rodriguez, V.A., Diament, M.J., Klein, S.M.: Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinfl ammatory drugs. Int J Cancer 110, S. 825 – 30 (2004).

58. (95) Matranga, C.B., Shapiro, G.I.: Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 62: S. 1707-1717 (2002).

59. (100) Motwani, M., Delohery, T.M., Schwartz, G.K.: Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5(7): S. 1876-83 (1999).

60. (139) Senderowicz, A.M.: Small-molecule cyclin-dependent kinase modulators. Oncogene 22: S. 6609-6620 (2003).

61. (186) Yu, Q., Geng, Y., Sicinski, P.: Specific protection against breast cancers by cyclin D1 ablation. Nature 411: S. 1017-1021 (2001).

62. (171) Vermeulen, K., Van Bockstaele, D.R., and Berneman, Z.N.: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36. S. 131–149 (2003).

63. Senderowicz, A.M.: The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologists 7: S. 12-19 (2002).

64. Wu, T., Leng, J., Han, C., Demetris, A.J.: The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3(3): S. 299-307 (2004)

65. Wang, H.J., Peng. Z.L., Liu, X.Q., Yang, K.X., Lou, J.Y., Luo, F.M..: The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer. Abstract in English. Article in Chinese. Sichuan Da Xue Xue Bao Yi Xue Ban 38(3):428-32 (2007).

66. Tallarida, Ronald J.: The interaction index: a measure of drug synergism. Pain 98, S. 163-168 (2002).

67. Yu, C., Rahmani, M., Dai, Y., Conrad, D., Krystal, G., Dent, P., Grant, S.: The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 15;63(8). S. 1822-33 (2003).

68. Norel, X., Brink, C.: The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. [Journal] // Pharmacol Ther 103:81–94 (2004).

69. (153) Song, Y., Shen, K., Tang, P.P.: Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 42(11): S. 761-4 (2007) (154) Song, Y.C., Kim, S.H., Juhnn, Y.S., Song, Y.S.: Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells. Ann N Y Acad Sci 1095: 26-34 (2007).

70. (170) Van Veldhuizen, P.J., Faulkner, J.R., Lara, P.N. Jnr., Gumerlock, P.H., Goodwin, J.W., Dakhil, S.R., Gross, H.M., Flanigan, R.C., Crawford, E.D. und Group Southwest Oncology: A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol 56(1). S. 39-45 (2005).

71. Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C.T., Scozzafava, A., Klebe, G.: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47: S. 550–555 (2004).

72. Tavassoli, F.A., Devilee, P.: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon : IARC Press (2003).

73. (187) Yuan, A., Yu, C.J. and Shun, C.T. et al.: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int Journal Cancer 115, S. 545– 555 (2005).

74. Maier, T.J., Janssen, A., Schmidt, R., Geisslinger, G., Grosch, S.: Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2- independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 19 : S. 1353-5 (2005).

75. Tsujii, M., Kawano, S., DuBoi,s R.N.: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336–40 (1997).

76. Testa, J.R., Bellacosa, A.: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 25;98(20):S. 10983-5 (2001).

77. Shapiro, G.I.: Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. J Clin Oncol 24 (11): S. 1770-1783 (2006).